Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer

Anne S. Tsao, Xi Ming Tang, Bradley Sabloff, Lianchun Xiao, Hisayuki Shigematsu, Jack Roth, Margaret Spitz, Waun Ki Hong, Adi Gazdar, Ignacio Wistuba

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

BACKGROUND: The authors sought to define clinicopathologic features associated with mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC). METHODS: The authors evaluated surgically resected NSCLC tumors for EGFR (exons 18-21) and KRAS (codons 12-13) mutations and immunohistochemistry (EGFR, phosphorylated-EGFR, and HER2/Neu), and correlated results with clinical outcome and patient and disease features. After their analysis on 159 patients was completed, they selected a second cohort of Asian patients (n = 22) and compared EGFR mutation results to place of birth and immigration to the United States. RESULTS: Of 159 patients, 14 had EGFR mutations and 18 had KRAS mutations. EGFR mutations were associated with adenocarcinoma (p = 0.002), female gender (p = 0.02), never-smoking (p < 0.0001), Asian ethnicity (p = 0.005), air bronchograms (p = 0.004), and multiple wedge resections (p = 0.03). Although statistical significance was not reached, a higher incidence of synchronous primary cancers (36% versus 17%; p = 0.09) and a smaller median tumor size (11.8 cm versus 24.0 cm; p = 0.24) were seen. There was no difference in disease-free survival; however, median overall survival in patients with EGFR mutations was shorter (3.49 versus 4.29 years; p = 0.85). EGFR mutation did not correlate with immunohistochemistry. In the second cohort of 22 Asian patients, 12 (55%) had the mutation. Of interest, there was no geographic difference in incidence of EGFR mutation. Asian women with the EGFR mutation developed adenocarcinoma at an earlier age than other lung cancer patients. CONCLUSION: There is a distinct clinical profile for NSCLC patients with the EGFR mutation. However, this mutation does not alter disease-free survival and is likely attributable to an inherited susceptibility instead of an environmental effect.

Original languageEnglish (US)
Pages (from-to)231-239
Number of pages9
JournalJournal of Thoracic Oncology
Volume1
Issue number3
StatePublished - Mar 2006

Fingerprint

erbB-1 Genes
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Mutation
Disease-Free Survival
Adenocarcinoma
Immunohistochemistry
Neoplasms
Incidence
Emigration and Immigration
Codon

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Tsao, A. S., Tang, X. M., Sabloff, B., Xiao, L., Shigematsu, H., Roth, J., ... Wistuba, I. (2006). Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. Journal of Thoracic Oncology, 1(3), 231-239.

Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. / Tsao, Anne S.; Tang, Xi Ming; Sabloff, Bradley; Xiao, Lianchun; Shigematsu, Hisayuki; Roth, Jack; Spitz, Margaret; Hong, Waun Ki; Gazdar, Adi; Wistuba, Ignacio.

In: Journal of Thoracic Oncology, Vol. 1, No. 3, 03.2006, p. 231-239.

Research output: Contribution to journalArticle

Tsao, AS, Tang, XM, Sabloff, B, Xiao, L, Shigematsu, H, Roth, J, Spitz, M, Hong, WK, Gazdar, A & Wistuba, I 2006, 'Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer', Journal of Thoracic Oncology, vol. 1, no. 3, pp. 231-239.
Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. Journal of Thoracic Oncology. 2006 Mar;1(3):231-239.
Tsao, Anne S. ; Tang, Xi Ming ; Sabloff, Bradley ; Xiao, Lianchun ; Shigematsu, Hisayuki ; Roth, Jack ; Spitz, Margaret ; Hong, Waun Ki ; Gazdar, Adi ; Wistuba, Ignacio. / Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. In: Journal of Thoracic Oncology. 2006 ; Vol. 1, No. 3. pp. 231-239.
@article{42109fa45723465e910a03caae0f16c5,
title = "Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer",
abstract = "BACKGROUND: The authors sought to define clinicopathologic features associated with mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC). METHODS: The authors evaluated surgically resected NSCLC tumors for EGFR (exons 18-21) and KRAS (codons 12-13) mutations and immunohistochemistry (EGFR, phosphorylated-EGFR, and HER2/Neu), and correlated results with clinical outcome and patient and disease features. After their analysis on 159 patients was completed, they selected a second cohort of Asian patients (n = 22) and compared EGFR mutation results to place of birth and immigration to the United States. RESULTS: Of 159 patients, 14 had EGFR mutations and 18 had KRAS mutations. EGFR mutations were associated with adenocarcinoma (p = 0.002), female gender (p = 0.02), never-smoking (p < 0.0001), Asian ethnicity (p = 0.005), air bronchograms (p = 0.004), and multiple wedge resections (p = 0.03). Although statistical significance was not reached, a higher incidence of synchronous primary cancers (36{\%} versus 17{\%}; p = 0.09) and a smaller median tumor size (11.8 cm versus 24.0 cm; p = 0.24) were seen. There was no difference in disease-free survival; however, median overall survival in patients with EGFR mutations was shorter (3.49 versus 4.29 years; p = 0.85). EGFR mutation did not correlate with immunohistochemistry. In the second cohort of 22 Asian patients, 12 (55{\%}) had the mutation. Of interest, there was no geographic difference in incidence of EGFR mutation. Asian women with the EGFR mutation developed adenocarcinoma at an earlier age than other lung cancer patients. CONCLUSION: There is a distinct clinical profile for NSCLC patients with the EGFR mutation. However, this mutation does not alter disease-free survival and is likely attributable to an inherited susceptibility instead of an environmental effect.",
author = "Tsao, {Anne S.} and Tang, {Xi Ming} and Bradley Sabloff and Lianchun Xiao and Hisayuki Shigematsu and Jack Roth and Margaret Spitz and Hong, {Waun Ki} and Adi Gazdar and Ignacio Wistuba",
year = "2006",
month = "3",
language = "English (US)",
volume = "1",
pages = "231--239",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

TY - JOUR

T1 - Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer

AU - Tsao, Anne S.

AU - Tang, Xi Ming

AU - Sabloff, Bradley

AU - Xiao, Lianchun

AU - Shigematsu, Hisayuki

AU - Roth, Jack

AU - Spitz, Margaret

AU - Hong, Waun Ki

AU - Gazdar, Adi

AU - Wistuba, Ignacio

PY - 2006/3

Y1 - 2006/3

N2 - BACKGROUND: The authors sought to define clinicopathologic features associated with mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC). METHODS: The authors evaluated surgically resected NSCLC tumors for EGFR (exons 18-21) and KRAS (codons 12-13) mutations and immunohistochemistry (EGFR, phosphorylated-EGFR, and HER2/Neu), and correlated results with clinical outcome and patient and disease features. After their analysis on 159 patients was completed, they selected a second cohort of Asian patients (n = 22) and compared EGFR mutation results to place of birth and immigration to the United States. RESULTS: Of 159 patients, 14 had EGFR mutations and 18 had KRAS mutations. EGFR mutations were associated with adenocarcinoma (p = 0.002), female gender (p = 0.02), never-smoking (p < 0.0001), Asian ethnicity (p = 0.005), air bronchograms (p = 0.004), and multiple wedge resections (p = 0.03). Although statistical significance was not reached, a higher incidence of synchronous primary cancers (36% versus 17%; p = 0.09) and a smaller median tumor size (11.8 cm versus 24.0 cm; p = 0.24) were seen. There was no difference in disease-free survival; however, median overall survival in patients with EGFR mutations was shorter (3.49 versus 4.29 years; p = 0.85). EGFR mutation did not correlate with immunohistochemistry. In the second cohort of 22 Asian patients, 12 (55%) had the mutation. Of interest, there was no geographic difference in incidence of EGFR mutation. Asian women with the EGFR mutation developed adenocarcinoma at an earlier age than other lung cancer patients. CONCLUSION: There is a distinct clinical profile for NSCLC patients with the EGFR mutation. However, this mutation does not alter disease-free survival and is likely attributable to an inherited susceptibility instead of an environmental effect.

AB - BACKGROUND: The authors sought to define clinicopathologic features associated with mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC). METHODS: The authors evaluated surgically resected NSCLC tumors for EGFR (exons 18-21) and KRAS (codons 12-13) mutations and immunohistochemistry (EGFR, phosphorylated-EGFR, and HER2/Neu), and correlated results with clinical outcome and patient and disease features. After their analysis on 159 patients was completed, they selected a second cohort of Asian patients (n = 22) and compared EGFR mutation results to place of birth and immigration to the United States. RESULTS: Of 159 patients, 14 had EGFR mutations and 18 had KRAS mutations. EGFR mutations were associated with adenocarcinoma (p = 0.002), female gender (p = 0.02), never-smoking (p < 0.0001), Asian ethnicity (p = 0.005), air bronchograms (p = 0.004), and multiple wedge resections (p = 0.03). Although statistical significance was not reached, a higher incidence of synchronous primary cancers (36% versus 17%; p = 0.09) and a smaller median tumor size (11.8 cm versus 24.0 cm; p = 0.24) were seen. There was no difference in disease-free survival; however, median overall survival in patients with EGFR mutations was shorter (3.49 versus 4.29 years; p = 0.85). EGFR mutation did not correlate with immunohistochemistry. In the second cohort of 22 Asian patients, 12 (55%) had the mutation. Of interest, there was no geographic difference in incidence of EGFR mutation. Asian women with the EGFR mutation developed adenocarcinoma at an earlier age than other lung cancer patients. CONCLUSION: There is a distinct clinical profile for NSCLC patients with the EGFR mutation. However, this mutation does not alter disease-free survival and is likely attributable to an inherited susceptibility instead of an environmental effect.

UR - http://www.scopus.com/inward/record.url?scp=33748429730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748429730&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 231

EP - 239

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -